Forecast

There is no analyst data available for this company.

News Go to news feed

MediPharm Labs Q1 2026: revenue falls, adjusted EBITDA positive for first time

MediPharm Labs reported Q1 2026 revenue of CAD 9.0 million (‑16.7% year‑on‑year) but achieved a positive adjusted EBITDA of CAD 0.1 million. Net loss widened to CAD 0.9 million, gross margin was 37%. International revenue accounted for 51% of sales. The company plans annual savings of CAD 1.0 million through restructurings and holds CAD 9.9 million in cash. The stock rose 12.5% in pre-market trading after the results were released. » More on de.investing.com
MediPharm Labs beats Q4 revenue forecast by 5.79% and highlights international sales

MediPharm Labs reported Q4 2025 revenue of CAD 14.06 million versus expected CAD 13.29 million (+5.79%) and an EPS of zero, in line with forecasts. The stock rose 7.69% in premarket trading. International medical cannabis sales contributed over 50% of total revenue; the fiscal year recorded revenue growth of 8% and an improved net loss position of CAD 8.3 million. The company emphasizes expansion into foreign markets and the expansion of EU‑GMP capacity for 2026. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, MediPharm Labs has already paid 0,0431€ in dividends. The last payout was in April 2022.

Financials

In the last quarter, MediPharm Labs had revenue of 6,16 Mio€ and net profit of 2,47k€

(EUR)	Jun 2026	YoY
Revenue	+6,16 Mio	16,34%
Gross profit	+2,65 Mio	27,56%
Net profit	+2,47k	100,10%
EBITDA	+136,35k	106,55%

Fundamentals

Metric	Value
Market capitalization	+20,42 Mio€
Number of shares	424,86 Mio
52-week high/low	+0,0652€ - +0,0352€
Dividends	No
Beta	0,95
P/E ratio	−6,90
PEG ratio	−0,10
P/B ratio	+0,96
P/S ratio	+0,82

Company profile

MediPharm Labs Corp. ist ein pharmazeutisches Unternehmen, das Cannabisöl und -konzentrate in pharmazeutischer Qualität sowie fortschrittliche derivative Produkte in Kanada, Australien, Deutschland und international herstellt und vertreibt. Das Unternehmen formuliert, verarbeitet, verpackt und vertreibt Cannabisextrakte und fortschrittliche Produkte auf Cannabinoidbasis. Das Unternehmen bietet auch GMP-Blumenbeschaffung, Verpackung und Vertriebsdienstleistungen an. MediPharm Labs Corp. wurde im Jahr 2015 gegründet und hat seinen Hauptsitz in Barrie, Kanada.